245 related articles for article (PubMed ID: 21909350)
21. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
22. Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Wang GH; Jin J; Sun LZ
Endocr J; 2018 Sep; 65(9):903-913. PubMed ID: 29925744
[TBL] [Abstract][Full Text] [Related]
23. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Packard CJ
Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
[TBL] [Abstract][Full Text] [Related]
25. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
Rosenson RS; Stafforini DM
J Lipid Res; 2012 Sep; 53(9):1767-82. PubMed ID: 22665167
[TBL] [Abstract][Full Text] [Related]
26. Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Chen C; Zhu J; Deng X; Yang Z; Lin W; Ma Y; Huang S; Chen L; Liu Y; Zhu F
J Clin Neurosci; 2021 Jun; 88():232-236. PubMed ID: 33992190
[TBL] [Abstract][Full Text] [Related]
27. Regression of atherosclerosis in apolipoprotein E-deficient mice by lentivirus-mediated gene silencing of lipoprotein-associated phospholipase A2.
Zhang H; Zhang J; Shen D; Zhang L; He F; Dang Y; Li L
Biochem Biophys Res Commun; 2012 Oct; 427(3):557-62. PubMed ID: 23022183
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of serum LP-PLA2 and hs-CRP in unstable atherosclerotic plaques.
Du Y; Wei F; Dong Z; Liu J; Jiang W; Lu Q
Clin Exp Hypertens; 2011; 33(2):113-6. PubMed ID: 21269060
[TBL] [Abstract][Full Text] [Related]
29. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
Daida H; Iwase T; Yagi S; Ando H; Nakajima H
Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
[TBL] [Abstract][Full Text] [Related]
30. Melatonin suppresses atherosclerosis by ferroptosis inhibition via activating NRF2 pathway.
Tao Y; Zhao Q; Lu C; Yong W; Xu M; Wang Z; Leng X
FASEB J; 2024 May; 38(10):e23678. PubMed ID: 38780199
[TBL] [Abstract][Full Text] [Related]
31. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
[TBL] [Abstract][Full Text] [Related]
32. Darapladib for the treatment of cardiovascular disease.
Campos CM; Suwannasom P; Koenig W; Serruys PW; Garcia-Garcia HM
Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):33-48. PubMed ID: 25521799
[TBL] [Abstract][Full Text] [Related]
33. Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.
Guibbal F; Bénard S; Patché J; Meneyrol V; Couprie J; Yong-Sang J; Meilhac O; Jestin E
Bioorg Med Chem Lett; 2018 Feb; 28(4):787-792. PubMed ID: 29336874
[TBL] [Abstract][Full Text] [Related]
34. Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A
Otsuka F; Zhao X; Trout HH; Qiao Y; Wasserman BA; Nakano M; Macphee CH; Brandt M; Krug-Gourley S; Guo L; Ladich ER; Cheng Q; Davis HR; Finn AV; Virmani R; Kolodgie FD
Atherosclerosis; 2017 Dec; 267():78-89. PubMed ID: 29101839
[TBL] [Abstract][Full Text] [Related]
35. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.
Hu C; Tompson D; Magee M; Chen Q; Liu YM; Zhu W; Zhao H; Gross AS; Liu Y
PLoS One; 2015; 10(10):e0139862. PubMed ID: 26465780
[TBL] [Abstract][Full Text] [Related]
36. Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.
De Stefano A; Mannucci L; Massoud R; Bernardini S; Cortese C
Biochem Med (Zagreb); 2017 Oct; 27(3):030701. PubMed ID: 28900364
[TBL] [Abstract][Full Text] [Related]
37. The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.
Stewart RA; White HD
Curr Atheroscler Rep; 2011 Apr; 13(2):132-7. PubMed ID: 21207201
[TBL] [Abstract][Full Text] [Related]
38. Anti-atherogenic effect of Humulus japonicus in apolipoprotein E-deficient mice.
Lim H; Noh JR; Kim YH; Hwang JH; Kim KS; Choi DH; Go MJ; Han SS; Oh WK; Lee CH
Int J Mol Med; 2016 Oct; 38(4):1101-10. PubMed ID: 27600281
[TBL] [Abstract][Full Text] [Related]
39. Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Wihastuti TA; Heriansyah T; Hanifa H; Andarini S; Sholichah Z; Sulfia YH; Adam AA; Refialdinata J; Lutfiana NC
Endocr Regul; 2018 Apr; 52(2):69-75. PubMed ID: 29715185
[TBL] [Abstract][Full Text] [Related]
40. [Impact of exogenous fibroblast growth factor 21 on atherosclerosis in apolipoprotein E deficient mice].
Wu X; Lü Y; Fu K; Wang S; Zhao D; Peng H; Fan Q; Lü Y; Xin M; Liu J
Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Feb; 42(2):126-31. PubMed ID: 24735623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
